INTRAVASCULAR LITHOTRIPSY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Intravascular Lithotripsy Market Size and Forecast – 2025 to 2032

The Global Intravascular Lithotripsy Market is estimated to be valued at USD 160.4 Mn in 2025 and is expected to reach USD 434.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 15.3% from 2025 to 2032. This significant growth reflects increasing adoption of intravascular lithotripsy technology in the treatment of cardiovascular calcifications, driven by advancements in minimally invasive procedures and rising prevalence of cardiovascular diseases globally.

Key Takeaways of the Global Intravascular Lithotripsy Market

• In 2025, intravascular lithotripsy balloons are expected to hold the largest market share at 56.3%, primarily due to their ability to combine mechanical dilation with lithotripsy for modifying calcified plaque.
• In the application sector, coronary artery disease (CAD) remains the dominant segment, contributing an estimated 34.2% to the global intravascular lithotripsy market in 2025.
• Among technological segments, Electrohydraulic Lithotripsy (EHL) leads the market, with an estimated share of 42.2% in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 26.2% in 2025.

Market Overview

Market trends highlight a shift towards innovative and patient-friendly treatment options, with intravascular lithotripsy gaining traction due to its efficacy in managing complex arterial calcifications without the risks associated with traditional methods. Additionally, growing awareness among healthcare providers, improved reimbursement policies, and expanding applications beyond peripheral artery disease are fueling market expansion. The integration of real-time imaging and enhanced safety profiles further accelerates adoption in both developed and emerging healthcare markets.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Intravascular Lithotripsy Market Insights, By Product Type - Intravascular Lithotripsy Balloons Dominate Due to their Revolutionary Design and Clinical Precision

In terms of product type, intravascular lithotripsy balloons contribute the highest share of the market with an estimated 56.3% in 2025 owing to their unique ability to combine mechanical dilation with lithotripsy-enabled calcified plaque modification. These balloons are pivotal in treating heavily calcified vascular lesions that were previously challenging to manage using conventional balloon angioplasty or atherectomy. The fundamental driver of this segment’s dominance lies in the clinical efficacy of intravascular lithotripsy (IVL) balloons to fracture calcified plaques safely and effectively without causing significant vessel injury. This precision in modifying plaque enhances vessel compliance, facilitating better stent deployment and improving long-term procedural outcomes.

Moreover, intravascular lithotripsy balloons have seen growing adoption due to their minimal procedural complexity and safety profile. Unlike standalone atherectomy devices that may carry risks of embolization or vessel trauma, IVL balloons deliver localized sonic pressure waves that selectively target calcification, preserving the surrounding soft tissue. The balloon-based platform also harmonizes well with the established interventional cardiology workflow, allowing physicians to integrate IVL into existing catheterization lab protocols without steep learning curves. This ease of use has accelerated acceptance globally among interventional specialists.

In November 2024, Amplitude Vascular Systems (AVS), a medical device company, initiated its POWER PAD II pivotal trial in the U.S. to evaluate the safety and efficacy of its Pulse Intravascular Lithotripsy System for treating moderate to severely calcified peripheral arterial disease (PAD). The first patient was enrolled at UnityPoint Trinity Medical Center in Iowa, marking a significant step in AVS's commitment to addressing complex arterial diseases.

Intravascular Lithotripsy Market Insights, By Application - Coronary Artery Disease Commands Dominant Market Share Due to Unmet Clinical Needs and Technological Advancements

In the application landscape, Coronary Artery Disease (CAD) maintains its position as the dominant segment contributing the highest share of the global intravascular lithotripsy market with an estimated 34.2% in 2025. The predominance of CAD as a target condition is largely driven by the critical prevalence of calcified coronary lesions, which present significant challenges to conventional percutaneous coronary interventions (PCI). Patients with heavily calcified plaques often experience suboptimal stent expansion and increased risk of restenosis or vessel dissection, underscoring the urgent clinical demand for improved therapeutic approaches.

The efficacy of intravascular lithotripsy in modifying calcified coronary plaques has positioned it as a breakthrough technology in CAD management. By delivering targeted shockwave energy, the technology alters the morphology of calcific deposits, thereby facilitating safer and more effective stent placement. This has not only expanded treatment options but also empowered clinicians to intervene in patient subsets previously considered high-risk or unsuitable for PCI due to severe calcification.

Intravascular Lithotripsy Market Insights, By Technology - The Electrohydraulic Lithotripsy (EHL) Segment Dominates the Intravascular Lithotripsy Market Due to its Advanced Ability to Effectively Treat Severely Calcified Coronary Lesions

Among the technological segments, Electrohydraulic Lithotripsy (EHL) is expected to command the highest share of the global intravascular lithotripsy market with a share of 42.2% in 2025, reflecting its foundational role in delivering effective energy for the fragmentation of calcified plaques. The preference for EHL technology is anchored in its ability to produce high-intensity shockwaves using electrohydraulic spark discharge, which translates into efficient and precise calcification disruption within vascular lesions.

In April 2025, Medtronic partnered with Dragonfly Endoscopy to distribute the Dragonfly pancreaticobiliary system in the U.S., enhancing stone clearance and biopsy accuracy. The system features a rotatable, flexible shaft and a 42% larger working channel, enabling the use of Electrohydraulic Lithotripsy (EHL) probes for improved diagnostic and therapeutic outcomes. Distribution will begin in 2025 at selected U.S. clinical centers.

EHL’s robust mechanism ensures that sonic pressure waves travel through fluid-filled catheters and balloons, targeting rigid calcium while sparing compliant vascular tissue, thereby reducing procedural complications such as dissections or perforations. The reliability and repeatability of energy delivery inherent to EHL systems provide clinicians with consistent treatment outcomes, fostering strong confidence in the technology during complex interventions.

Regional Insights

To learn more about this report, Download Free Sample

North America Intravascular Lithotripsy Market Analysis and Trends

North America’s dominance in the global intravascular lithotripsy market, with an estimated share of 38.3% in 2025, is driven by a mature healthcare infrastructure, advanced cardiovascular care protocols, and strong presence of leading medical device manufacturers. The U.S., in particular, benefits from supportive government policies that facilitate expedited regulatory approval and reimbursement for innovative cardiovascular therapies.

The high prevalence of vascular calcification disorders and rising geriatric population further fuel demand for intravascular lithotripsy devices. The ecosystem here thrives on extensive clinical research, widespread adoption of technologically advanced procedures, and strong collaboration between hospitals, research institutions, and industry players. For example, Philips Healthcare is a key player in the cardiovascular technology space, offering advanced imaging solutions that complement IVL treatments. Its Philips IntraSight system, which integrates with IVL devices, provides detailed vessel imaging, aiding in the precise placement of IVL catheters during procedures.

Asia Pacific Intravascular Lithotripsy Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth due to rising cardiovascular disease incidence, increasing healthcare expenditure with a share of 26.2% in 2025, and expanding healthcare infrastructure across emerging economies such as China, India, and Japan. Government initiatives aimed at improving access to advanced cardiovascular treatments, coupled with a growing middle class and heightened medical awareness, are accelerating device adoption.

On June 25, 2023, the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was launched, uniting patient organizations, health professionals, academia, and corporate partners to combat cardiovascular disease (CVD) across nine Asian countries. Headquartered in Singapore, the alliance is led by ACCESS Health International, a global health think-tank. With CVD being the leading cause of death in Asia Pacific, the alliance aims to raise awareness, promote scalable innovations, and emphasize the need for investments in tackling CVD to foster healthier societies and economies.

Intravascular Lithotripsy Market Outlook for Key Countries

U.S. Intravascular Lithotripsy Market

The U.S. intravascular lithotripsy market remains at the forefront of intravascular lithotripsy innovation, buoyed by leading medical device companies and a dynamic clinical research environment. Early adoption of new technologies by healthcare providers, supported by favorable Medicare reimbursements and a high rate of cardiovascular interventions, sustains strong demand. Shockwave Medical, with its flagship lithotripsy system, has substantially impacted clinical practice, complemented by other key players like Medtronic advancing device features and procedural efficacy.

In April 2025, Elixir Medical, a U.S.-based innovator in cardiovascular technologies, announced the European launch of its LithiX Hertz Contact (HC) Intravascular Lithotripsy (IVL) System following CE Mark approval under EU MDR. Unlike traditional IVL systems, LithiX operates without an external energy source, using Hertz Contact Stress mechanics to safely fracture calcium in moderate to severely calcified coronary artery lesions.

India Intravascular Lithotripsy Market

The intravascular lithotripsy market in India is experiencing significant growth, driven by advancements in medical technology, including AI integration, and an increasing prevalence of cardiovascular diseases. The rising incidence of conditions like calcified arterial lesions is boosting the demand for minimally invasive treatments like IVL. Additionally, improved healthcare infrastructure, wider access to specialized cardiac centers, and government support for medical innovation are further propelling market expansion. These factors are positioning IVL as a key solution in the treatment of cardiovascular diseases in India.

In April 2021, Apollo Hospitals, one of India's leading healthcare providers, successfully performed the country’s first intravascular lithotripsy (IVL) procedure for treating severely calcified carotid artery stenosis. Conducted at Apollo Health City, Hyderabad, the innovative procedure was used on a 75-year-old patient with recurrent strokes and heavily calcified carotid lesions.

China Intravascular Lithotripsy Market

China stands out in the Asia Pacific region due to major investments in healthcare modernization and increasing cardiovascular disease burden. Government policies incentivizing advanced medical device adoption, coupled with initiatives like the National Medical Products Administration's streamlined approvals, incentivize market entry and expansion. Global leaders have formed strategic partnerships with domestic healthcare providers and distributors to offer intravascular lithotripsy devices tailored to local needs. Efforts are underway to expand physician training and post-market clinical evidence, which collectively propel market growth.

In February 2025, MicroPort RotaPace, a subsidiary of MicroPort Coronary, received regulatory approval in China for its TomaHawk Integrated Coronary Intravascular Lithotripsy (IVL) System, offering an advanced solution for treating complex coronary artery disease. The system combines a disposable IVL balloon catheter with a treatment device, using high-energy shockwaves to fracture calcified plaques and improve stent placement. Notably, TomaHawk features the world’s first real-time balloon pressure monitoring and a patented electrode design that ensures safety and precision.

Japan Intravascular Lithotripsy Market

Japan’s sophisticated healthcare system, with one of the world’s highest standards for clinical care, supports steady intravascular lithotripsy market development. Reimbursement policies favor innovative cardiovascular treatments, encouraging medical institutions to integrate cutting-edge devices. Japan’s focus on aging population care further anchors demand for minimally invasive cardiovascular interventions.

 For example, Terumo Corporation has been instrumental in the evolution of intravascular imaging technologies, including intravascular ultrasound (IVUS), which are essential for assessing calcified lesions in coronary arteries. Its advancements in IVUS technology have significantly contributed to the safe and effective application of IVL in clinical settings.

End User Feedback and Unmet Needs in the Global Intravascular Lithotripsy Market

• End users in the global intravascular lithotripsy market, particularly healthcare providers and interventional cardiologists, consistently provide valuable feedback on the performance, accessibility, and integration of IVL technologies. A positive example of user satisfaction comes from Shockwave Medical’s Pulse IVL System, which has received praise for its ease of use and high procedural success rates in treating severely calcified coronary lesions. Interventional cardiologists have noted that the Electrohydraulic Lithotripsy (EHL) technology significantly reduces complications in complex procedures, particularly in high-risk patients. One key benefit is the system's ability to deliver precise, controlled shockwaves, improving patient outcomes by facilitating stent implantation in previously inaccessible lesions. This positive feedback highlights the technology’s clinical efficacy and its growing adoption in cardiology.
• However, concerns persist regarding cost and accessibility, particularly in emerging markets. A commonly cited issue is the high upfront cost of IVL devices and the ongoing costs associated with procedure execution, making them less affordable for many hospitals and healthcare facilities, especially in regions with limited resources. Despite the clinical benefits, the financial burden on institutions, compounded by a lack of reimbursement support in certain regions, hampers widespread adoption. Additionally, some healthcare providers have highlighted the lack of customization in the devices for specific patient populations, such as those with varying anatomical structures, which could improve the overall treatment effectiveness. These concerns underscore the unmet need for cost-effective, adaptable solutions that meet the diverse needs of healthcare systems globally. Addressing these gaps would create significant growth opportunities by expanding access to IVL technologies, improving customer retention through affordability and support, and inspiring further innovation in device customization and cost-efficiency.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In March 2025, Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in intravascular lithotripsy (IVL), launched the Shockwave Javelin Peripheral IVL Catheter in the U.S. This novel forward IVL platform is specifically designed to cross and modify heavily calcified, difficult-to-access lesions in patients with peripheral artery disease (PAD). With a 150 cm working length and a single distal emitter delivering up to 120 shockwave pulses, Javelin delivers energy directly at the site of occlusion, enhancing treatment precision.
• In March 2025, Abbott, a global healthcare leader known for its advanced cardiovascular technologies, initiated the TECTONIC Coronary IVL clinical trial in the U.S. to evaluate its investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe arterial calcification in patients with coronary artery disease (CAD). The system uses high-energy sound pressure waves to fracture calcium buildup and improve vessel preparation before stenting.
• In January 2025, Boston Scientific Corporation, a global leader in medical devices, announced its agreement to acquire Bolt Medical, Inc., a company it co-founded in 2019 to develop a laser-based intravascular lithotripsy (IVL) platform for treating coronary and peripheral artery disease (PAD). Boston Scientific, which already holds a 26% stake, will acquire the remaining 74% for USD 443 million, with up to USD 221 million in milestone payments. The Bolt IVL system, still investigational, uses acoustic pressure waves via balloon catheters to break up calcified lesions and features directional emitters for targeted energy delivery.
• In November 2024, Royal Philips, a global leader in health technology, launched the THOR IDE clinical trial in the U.S. to evaluate its innovative single-device solution that combines laser atherectomy and intravascular lithotripsy (IVL) for the treatment of peripheral artery disease (PAD). The first patient was successfully treated at the Cardiovascular Institute of the South in Louisiana. This first-of-its-kind device streamlines complex procedures by integrating two key PAD treatments, aiming to enhance procedural efficiency, reduce intervention time, and improve patient outcomes.

Top Strategies Followed by Global Intravascular Lithotripsy Market Players

• Established players are leading the intravascular lithotripsy market by making substantial investments in research and development (R&D) to develop high-performance devices that enhance clinical outcomes, procedural safety, and operational efficiency. These companies focus on introducing cutting-edge technologies and frequently form strategic partnerships with key industry stakeholders such as original equipment manufacturers (OEMs) and healthcare providers.
  • In January 2022, Cardiovascular Systems, Inc. (CSI), a U.S.-based medical device company specializing in innovative interventional treatments for coronary and peripheral artery disease, announced progress in developing its own intravascular lithotripsy (IVL) technology. The company has completed feasibility testing of a proprietary console and IVL balloon catheters, aimed at enhancing the treatment of calcified arterial lesions. CSI’s IVL system is designed to overcome limitations of current technologies and will complement its existing orbital atherectomy portfolio, expanding its presence in the vessel preparation market.

• Mid-level players in the intravascular lithotripsy market differentiate themselves by offering cost-effective solutions that balance quality with affordability, particularly catering to price-sensitive segments in developing regions. These companies focus on delivering value-driven products that meet clinical needs without the high price tags of premium devices. To boost their competitive edge, mid-sized players collaborate with technology developers, contract manufacturers, and regional distributors, which helps them scale operations, reduce time-to-market, and optimize resource utilization.
  • In June 2022, MUSC Health in South Carolina became one of the first to adopt intravascular lithotripsy (IVL), an USFDA-approved procedure that uses sonic pressure waves to safely treat calcified blockages. Dr. Gregory May highlighted IVL as a safer, more efficient alternative to traditional methods, showcasing how mid-level players are adopting innovative, affordable technologies for better patient outcomes.

• Small-scale players in the intravascular lithotripsy market focus on specialized product features or technological advancements that set their offerings apart from mainstream solutions. These companies develop more compact devices, enhanced imaging compatibility, and unique energy delivery mechanisms to address specific clinical challenges. Despite limited resources, they leverage cutting-edge technologies like artificial intelligence (AI) and advanced materials science to differentiate their products and create market opportunities.
  • For example, FastWave Medical is developing advanced IVL systems for treating calcific artery disease, focusing on compact, user-friendly designs. Its platforms aim to provide predictable sonic output and valuable procedural feedback, enhancing the effectiveness of treatments for both peripheral and coronary artery diseases.

Market Report Scope

Intravascular Lithotripsy Market Report Coverage

Intravascular Lithotripsy Market Dynamics

To learn more about this report, Download Free Sample

Intravascular Lithotripsy Market Driver - Rising Prevalence of Calcified Coronary and Peripheral Artery Diseases

The increasing incidence of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) significantly drives the adoption of intravascular lithotripsy (IVL) technology worldwide. These conditions, characterized by the hardening and calcification of arterial walls, pose severe challenges to conventional vascular interventions, often limiting the effectiveness of standard angioplasty and stenting procedures. IVL offers a minimally invasive solution by utilizing acoustic pressure waves to fracture calcified plaques, thereby facilitating vessel expansion and improving stent deployment.

According to American Heart Association, Inc., in June 2023, Peripheral Arterial and Aortic Diseases (PAAD) affect an estimated 113 million people aged 40 and above worldwide, with nearly half (43%) in low- and middle-income countries. The global prevalence is 1.5%, increasing with age, affecting 15-20% of those aged 70 and 20-30% of those aged 80 and older. Patients with aortic diseases are at risk for peripheral arterial diseases and vice versa. In June 2023, it was highlighted that PAD affects over 200 million people globally, with higher prevalence and worse outcomes in specific groups, particularly Black Americans. PAD leads to disability, depression, and limb amputations, and early identification is essential for better management and outcomes.

Intravascular Lithotripsy Market Opportunity - Growing Preference for Minimally Invasive Outpatient Procedures

The global intravascular lithotripsy market is poised to benefit significantly from the escalating preference for minimally invasive outpatient procedures across healthcare systems worldwide. Patients and healthcare providers alike are increasingly favoring outpatient interventions due to their numerous advantages, including reduced hospital stays, lower risk of hospital-acquired infections, quicker recovery times, and overall cost-effectiveness. Intravascular lithotripsy, which employs sonic pressure waves to fracture vascular calcifications, aligns well with these patient-centric trends by enabling effective treatment of calcified arterial lesions with minimal trauma.

 As more healthcare facilities and interventional cardiologists adopt this technology, there is an expanding opportunity to integrate intravascular lithotripsy in outpatient catheterization labs and ambulatory surgical centers. Additionally, advancements in imaging and catheter technologies enhance the precision and safety of these minimally invasive procedures, further encouraging adoption. With an aging global population and a rising prevalence of peripheral arterial disease and coronary artery disease, demand for less invasive, efficient vascular therapies continues to grow.

Analyst Opinion (Expert Opinion)

• The global intravascular lithotripsy market is being propelled by significant technological advancements, particularly in Electrohydraulic Lithotripsy (EHL) systems, which have revolutionized the treatment of severely calcified coronary lesions. Key drivers for market growth include the increasing demand for non-invasive, effective procedures, supported by favorable regulatory developments like the USFDA's approval for IVL devices. Additionally, the integration of AI-driven technologies into IVL systems, improving precision and reducing procedural risks, is fueling adoption, particularly in high-risk patient groups. However, challenges remain, including the high cost of devices and limited reimbursement policies in certain regions, which hinder broader accessibility and adoption. Opportunities exist in emerging markets, where advancements in healthcare infrastructure and rising awareness about coronary artery diseases present avenues for IVL penetration.
• Notable events such as the EuroPCR 2025 conference and TCT 2023 have been pivotal in advancing knowledge-sharing, policy formulation, and showcasing IVL technology to a global audience. These platforms contribute significantly to the dissemination of research findings, driving clinical adoption and policy changes. Moreover, Shockwave Medical's ongoing POWER PAD II trial and other pivotal studies are real-world examples of how industry initiatives are shaping the future of IVL. Collaborations between companies and government-backed healthcare initiatives are expected to foster innovation and improve patient access, further propelling the market.

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Intravascular Lithotripsy Balloons
    • Coronary IVL Balloons
    • Peripheral IVL Balloons
  • Integrated IVL Systems
    • Balloon Catheters
    • Generators / Consoles (Fixed and Portable)
    • Others (Connectors and Accessories)
• Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Coronary Artery Disease (CAD)
  • Calcified Coronary Lesions
  • Left Main Coronary Artery Disease
  • In-Stent Restenosis
  • Peripheral Artery Disease (PAD)
  • Iliac Artery Lesions
  • Femoral-Popliteal Lesions
  • Infrapopliteal Lesions
  • Others (Renal Artery Stenosis)
• Technology Insights (Revenue, USD Mn, 2020 - 2032)
  • Electrohydraulic Lithotripsy (EHL)
  • Ultrasound-based Lithotripsy
  • Laser-based Lithotripsy
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Adult
  • Geriatric
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Cardiac Catheterization Laboratories
  • Ambulatory Surgical Centers (ASCs)
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Shockwave Medical Inc.
  • FastWave Medical
  • MicroPort Scientific Corporation
  • Abbott Laboratories
  • Medtronic plc
  • Boston Scientific Corporation
  • Cook Medical LLC
  • BD (Becton, Dickinson and Company)
  • Braun
  • Olympus Corporation
  • Cordis
  • Biotronik

Sources

Primary Research Interviews

Industry Stakeholders List

• Cardiologists and Interventional Cardiologists
• Medical Device Manufacturers
• Health Economists
• Hospital Administrators
• Regulatory Experts
• Medical Technology Engineers

End Users List

• Cardiology Departments and Clinics
• Interventional Cardiology Practices
• Peripheral Arterial Disease (PAD) Treatment Centers
• Medical Practitioners and Surgeons

Government and International Databases

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Centers for Medicare & Medicaid Services (CMS)
• National Institutes of Health (NIH)
• World Health Organization (WHO)
• National Heart, Lung, and Blood Institute (NHLBI)
• Health Canada
• National Institute for Health and Care Excellence (NICE)

Trade Publications

• Cardiovascular Business
• Medical Device Network
• Cath Lab Digest
• Medscape Cardiology
• Endovascular Today
• The Cardiology Advisor

Academic Journals

• Journal of the American College of Cardiology (JACC)
• The Lancet Cardiovascular Medicine
• Circulation: Cardiovascular Interventions
• European Heart Journal - Cardiovascular Imaging
• Journal of Endovascular Therapy
• Journal of Vascular and Interventional Radiology
• American Journal of Cardiology
• Heart Rhythm Journal

Reputable Newspapers

• The New York Times (Health Section)
• The Guardian (Health Section)
• The Washington Post (Health Section)
• Reuters Health
• BBC Health
• The Wall Street Journal (Health and Medical Section)

Industry Associations

• American College of Cardiology (ACC)
• European Society of Cardiology (ESC)
• Society for Cardiovascular Angiography and Interventions (SCAI)
• European Association of Percutaneous Cardiovascular Interventions (EAPCI)
• American Heart Association (AHA)
• International Society for Cardiovascular Surgery (ISCVS)
• World Heart Federation (WHF)
• National Cardiovascular Data Registry (NCDR)

Public Domain Resources

• Global Health Data Exchange (GHDx)
• World Bank Health Statistics
• OECD Health Statistics
• National Library of Medicine
• Centers for Disease Control and Prevention (CDC)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years